| Market Cap | 165.45M | P/E | - | EPS this Y | 29.20% | Ern Qtrly Grth | - |
| Income | -197.68M | Forward P/E | -1.44 | EPS next Y | -8.00% | 50D Avg Chg | -53.00% |
| Sales | - | PEG | -0.06 | EPS past 5Y | - | 200D Avg Chg | -52.00% |
| Dividend | N/A | Price/Book | 0.42 | EPS next 5Y | 12.40% | 52W High Chg | -75.00% |
| Recommedations | 3.30 | Quick Ratio | 10.34 | Shares Outstanding | 52.61M | 52W Low Chg | 14.00% |
| Insider Own | 5.66% | ROA | -26.72% | Shares Float | 32.20M | Beta | 2.34 |
| Inst Own | 76.98% | ROE | -71.50% | Shares Shorted/Prior | 1.72M/1.74M | Price | 3.16 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,184,417 | Target Price | 2.75 |
| Oper. Margin | - | Earnings Date | Nov 12 | Volume | 1,009,541 | Change | 5.33% |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naΓ―ve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
| HC Wainwright & Co. | Neutral | Sep 24, 24 |
| HC Wainwright & Co. | Neutral | Sep 5, 24 |
| UBS | Neutral | Apr 4, 24 |
| Barclays | Underweight | Apr 1, 24 |
| UBS | Neutral | Dec 21, 23 |
| Capital One | Overweight | Nov 17, 23 |
| UBS | Neutral | Jul 27, 23 |
| Chardan Capital | Neutral | Jul 25, 23 |
| Barclays | Underweight | Jul 25, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| EHRLICH JASON | See Remarks See Remarks | Jun 14 | Sell | 9.33 | 3,390 | 31,629 | 61,924 | 06/16/23 |
| BORGESON JOHN A. | See Remarks See Remarks | Jun 14 | Sell | 9.33 | 4,197 | 39,158 | 178,077 | 06/16/23 |
| EHRLICH JASON | See Remarks See Remarks | Jun 15 | Sell | 7.12 | 3,487 | 24,827 | 56,920 | 06/17/22 |
| BORGESON JOHN A. | See Remarks See Remarks | Jun 15 | Sell | 7.12 | 4,343 | 30,922 | 173,755 | 06/17/22 |
| BAKER BROS. ADVISORS LP | Director Director | Jun 02 | Buy | 7.77 | 572,349 | 4,447,152 | 15,967,504 | 06/06/22 |
| BAKER BROS. ADVISORS LP | Director Director | May 16 | Buy | 5.9 | 456,690 | 2,694,471 | 15,142,074 | 05/18/22 |
| PERLROTH VICTOR | Chairman and CEO Chairman and CEO | Feb 24 | Sell | 9.09 | 1,340,000 | 12,180,600 | 2,168,038 | 02/28/22 |
| BAKER BROS. ADVISORS LP | Director Director | Feb 15 | Buy | 54.11 | 400,965 | 21,696,216 | 14,734,965 | 02/17/22 |
| BAKER BROS. ADVISORS LP | Director Director | Jan 27 | Buy | 52.1 | 347,665 | 18,113,346 | 14,364,512 | 01/31/22 |
| BAKER BROS. ADVISORS LP | Director Director | Jan 21 | Buy | 57.62 | 501,111 | 28,874,016 | 14,027,837 | 01/25/22 |
| EHRLICH JASON | See Remarks See Remarks | Jan 20 | Option | 10.29 | 6,950 | 71,516 | 58,491 | 01/24/22 |
| EHRLICH JASON | See Remarks See Remarks | Jan 20 | Sell | 64.9 | 6,950 | 451,055 | 51,541 | 01/24/22 |
| EHRLICH JASON | See Remarks See Remarks | Oct 20 | Option | 10.29 | 6,950 | 71,516 | 58,491 | 10/22/21 |
| EHRLICH JASON | See Remarks See Remarks | Oct 20 | Sell | 112.15 | 6,950 | 779,442 | 51,541 | 10/22/21 |
| BAKER BROS. ADVISORS LP | Director Director | Sep 09 | Buy | 93.12 | 57,501 | 5,354,493 | 13,269,155 | 09/09/21 |